Item 8.01 Other Events.

On May 15, 2020, Blueprint Medicines Corporation issued a press release announcing that the U.S. Food and Drug Administration has issued a complete response letter for the new drug application of avapritinib for the treatment of adults with unresectable or metastatic fourth-line gastrointestinal stromal tumor. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.


Exhibit No.    Description
99.1             Press release issued by Blueprint Medicines Corporation on May
               15, 2020
104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document)




                                       2

© Edgar Online, source Glimpses